Garima Sharma։ The 1st International Consensus on GLP-1RAs Across Women’s Reproductive Life Course
Garima Sharma, Director of Women’s Cardiovascular Health at Inova Health System, shared a post on LinkedIn about a paper by Sarah Dib et al. published in The Lancet Obstetrics, Gynaecology, and Women’s Health:
“The first international consensus recommendations from The Lancet Group on the use of GLP-1 receptor agonists across the reproductive life course in women with diabetes were developed by integrating a systematic review and meta-analysis of more than 43 000 women exposed to GLP-1 receptor agonists, expert consensus from 42 specialists with international representation, and input from 60 women with lived experience.
Available evidence, predominantly in women with type 2 diabetes, suggests that there is no increase in congenital anomaly risk following first-trimester discontinuation of GLP-1 receptor agonists, compared with no GLP-1 receptor agonist exposure, but important uncertainties remain regarding pregnancy loss, pregnancy exposure beyond the first trimester, and postpartum use.
The consensus panel supported GLP-1 receptor agonist use for preconception metabolic optimisation where needed in women with type 2 diabetes and recognised potential benefits in women with type 1 diabetes and previous gestational diabetes, although direct evidence in these groups is scarce.
The consensus recommendations should be interpreted in the context of little direct evidence and low certainty. Future studies focused on fertility, breastfeeding, and lactation impact, etc are needed.”
Title: Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement.
Authors: Sarah Dib, Matthew J Savage, Dawn Adams, Melanie J Davies, Rita Forde, Angela C Flynn, Paul W Franks, Alison Harte, Ritwika Mallik, Susan E Ozanne, Caroline Ovadia, Dimitris Papamargaritis, Rebecca M Reynolds, Naveed Sattar, Sara G I Suliman, Tricia Tan, Jovanna Tsoutsouki, Georgia Weston, Sara L White, Claire L Meek, on behalf of the GLP-1 Receptor Agonist Diabetes in Pregnancy Consensus Group.
You can read the Full Article in The Lancet Obstetrics, Gynaecology, and Women’s Health.

Stay informed with the latest updates in fertility and reproductive medicine on Fertility News.
-
Nov 18, 2026, 18:26Ritu Anand: We’ve Been Talking about Her Fertility – It’s Time to Talk about His
-
Nov 18, 2026, 18:20Sean Lauber: Is It Safe to Thaw and Rebiopsy an Embryo?
-
Nov 18, 2026, 18:14Arsiak Vartenian: 8 Years of Answering “Do You Have Kids?” Is a Long Time
-
Nov 18, 2026, 18:09Esther Eleboh: When the Same Protocol Produces Completely Different Embryo Outcomes
-
Nov 18, 2026, 18:05Resa Nabor: Having PCOS Doesn’t Make You Less of a Woman or Less Deserving of Love
-
Nov 18, 2026, 17:47Diana Kayal: Co-Chairing the 3rd International Conference on Gynecology and Women’s Health
-
Nov 18, 2026, 17:44Karthik Raj: Oocyte Quality Is Not Determined at Retrieval Alone
-
Nov 18, 2026, 17:41Tazeen Farhan: 10 Small Lifestyle Changes to Support Reproductive Health
-
Nov 18, 2026, 17:35Chanju Jung: Nature Paper Explores Base Editing in Human Embryos
